LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 35

Search options

  1. Article: Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates.

    Petty, Nicholas E / Radtke, Stefan / Fields, Emily / Humbert, Olivier / Llewellyn, Mallory J / Laszlo, George S / Zhu, Haiying / Jerome, Keith R / Walter, Roland B / Kiem, Hans-Peter

    Molecular therapy. Methods & clinical development

    2023  Volume 31, Page(s) 101121

    Abstract: Current immunotherapeutic targets are often shared between neoplastic and normal hematopoietic stem and progenitor cells (HSPCs), leading to unwanted on-target, off-tumor toxicities. Deletion or modification of such targets to protect normal HSPCs is, ... ...

    Abstract Current immunotherapeutic targets are often shared between neoplastic and normal hematopoietic stem and progenitor cells (HSPCs), leading to unwanted on-target, off-tumor toxicities. Deletion or modification of such targets to protect normal HSPCs is, therefore, of great interest. Although HSPC modifications commonly aim to mimic naturally occurring phenotypes, the long-term persistence and safety of gene-edited cells need to be evaluated. Here, we deleted the V-set domain of CD33, the immune-dominant domain targeted by most anti-CD33 antibodies used to treat CD33-positive malignancies, including acute myeloid leukemia, in the HSPCs of two rhesus macaques, performed autologous transplantation after myeloablative conditioning, and followed the animals for up to 3 years. CD33-edited HSPCs engrafted without any delay in recovery of neutrophils, the primary cell type expressing CD33. No impact on the blood composition, reconstitution of the bone marrow stem cell compartment, or myeloid differentiation potential was observed. Up to 20% long-term gene editing in HSPCs and blood cell lineages was seen with robust loss of CD33 detection on myeloid lineages. In conclusion, deletion of the V-set domain of CD33 on HSPCs, progenitors, and myeloid lineages did not show any adverse effects on their homing and engraftment potential or the differentiation and functionality of myeloid progenitors and lineages.
    Language English
    Publishing date 2023-09-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2872938-9
    ISSN 2329-0501 ; 2329-0501
    ISSN (online) 2329-0501
    ISSN 2329-0501
    DOI 10.1016/j.omtm.2023.101121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: [

    Laszlo, George S / Sandmaier, Brenda M / Kehret, Allie R / Orozco, Johnnie J / Hamlin, Donald K / Dexter, Shannon L / Lim, Sheryl Y T / Cole, Frances M / Huo, Jenny / Wilbur, D Scott / Walter, Roland B

    Leukemia & lymphoma

    2023  Volume 64, Issue 7, Page(s) 1335–1339

    MeSH term(s) Humans ; Radioimmunotherapy ; Astatine ; Sialic Acid Binding Ig-like Lectin 2 ; Antibodies, Monoclonal ; Neoplasms
    Chemical Substances Astatine (XI595HAL7H) ; Sialic Acid Binding Ig-like Lectin 2 ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-05-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2023.2210710
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET

    Lunn-Halbert, Margaret C / Laszlo, George S / Erraiss, Sarah / Orr, Mark T / Jessup, Heidi K / Thomas, Heather J / Chan, Henry / Jahromi, Mahan A / Lloyd, Jonathan / Cheung, Ann F / Chang, Gregory P / Dichwalkar, Tanmay / Fallon, Daniel / Grinberg, Asya / Rodríguez-Arbolí, Eduardo / Lim, Sheryl Y T / Kehret, Allie R / Huo, Jenny / Cole, Frances M /
    Scharffenberger, Samuel C / Walter, Roland B

    Cancers

    2024  Volume 16, Issue 5

    Abstract: Increasing efforts are focusing on natural killer (NK) cell immunotherapies for AML. Here, we characterized CC-96191, a novel CD33/CD16a/NKG2D immune-modulating ... ...

    Abstract Increasing efforts are focusing on natural killer (NK) cell immunotherapies for AML. Here, we characterized CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET
    Language English
    Publishing date 2024-02-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16050877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy.

    Borot, Florence / Humbert, Olivier / Newby, Gregory A / Fields, Emily / Kohli, Sajeev / Radtke, Stefan / Laszlo, George S / Mayuranathan, Thiyagaraj / Ali, Abdullah Mahmood / Weiss, Mitchell J / Yen, Jonathan S / Walter, Roland B / Liu, David R / Mukherjee, Siddhartha / Kiem, Hans-Peter

    bioRxiv : the preprint server for biology

    2023  

    Language English
    Publishing date 2023-02-23
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.02.23.529353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.

    Godwin, Colin D / Bates, Olivia M / Jean, Sae Rin / Laszlo, George S / Garling, Eliotte E / Beddoe, Mary E / Cardone, Michael H / Walter, Roland B

    Leukemia & lymphoma

    2020  Volume 61, Issue 12, Page(s) 2990–2994

    MeSH term(s) Apoptosis ; Apoptosis Regulatory Proteins ; Calicheamicins ; Humans ; Immunoconjugates/therapeutic use ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Proto-Oncogene Proteins c-bcl-2/genetics
    Chemical Substances Apoptosis Regulatory Proteins ; Calicheamicins ; Immunoconjugates ; Proto-Oncogene Proteins c-bcl-2
    Language English
    Publishing date 2020-07-04
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1786553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.

    Godwin, Colin D / Bates, Olivia M / Garling, Eliotte E / Beddoe, Mary E / Laszlo, George S / Walter, Roland B

    British journal of haematology

    2020  Volume 189, Issue 1, Page(s) e9–e13

    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/immunology ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Antibodies, Bispecific/pharmacology ; Antineoplastic Agents, Immunological/pharmacology ; Cell Line, Tumor ; Humans ; Immunity, Cellular/drug effects ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/immunology ; Neoplasm Proteins/metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology ; T-Lymphocytes/enzymology ; T-Lymphocytes/immunology ; T-Lymphocytes/pathology
    Chemical Substances Antibodies, Bispecific ; Antineoplastic Agents, Immunological ; Neoplasm Proteins ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; ibrutinib (1X70OSD4VX) ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; BTK protein, human (EC 2.7.10.2)
    Language English
    Publishing date 2020-02-04
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.16406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The past and future of CD33 as therapeutic target in acute myeloid leukemia.

    Laszlo, George S / Estey, Elihu H / Walter, Roland B

    Blood reviews

    2014  Volume 28, Issue 4, Page(s) 143–153

    Abstract: CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has therefore been exploited as target for therapeutic antibodies for many ... ...

    Abstract CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has therefore been exploited as target for therapeutic antibodies for many years. The improved survival seen in many patients when the antibody-drug conjugate, gemtuzumab ozogamicin, is added to conventional chemotherapy validates this approach. However, many attempts with unconjugated or conjugated antibodies have been unsuccessful, highlighting the challenges of targeting CD33 in AML. With the development of improved immunoconjugates and CD33-directed strategies that harness immune effector cells, therapeutics with enhanced efficacy may soon become available. Toxic effects on normal hematopoietic cells may increase in parallel with this increased efficacy and demand new supportive care measures, including possibly rescue with donor cells, to minimize morbidity and mortality from drug-induced cytopenias and to optimize treatment outcomes with these agents in patients with AML.
    MeSH term(s) Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Humans ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; Immunotherapy ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Molecular Targeted Therapy ; Sialic Acid Binding Ig-like Lectin 3/antagonists & inhibitors ; Sialic Acid Binding Ig-like Lectin 3/metabolism
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Immunoconjugates ; Sialic Acid Binding Ig-like Lectin 3
    Language English
    Publishing date 2014-07
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 639015-8
    ISSN 1532-1681 ; 0268-960X
    ISSN (online) 1532-1681
    ISSN 0268-960X
    DOI 10.1016/j.blre.2014.04.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.

    Godwin, Colin D / Laszlo, George S / Fiorenza, Salvatore / Garling, Eliotte E / Phi, Tinh-Doan / Bates, Olivia M / Correnti, Colin E / Hoffstrom, Benjamin G / Lunn, Margaret C / Humbert, Olivier / Kiem, Hans-Peter / Turtle, Cameron J / Walter, Roland B

    Leukemia

    2021  Volume 35, Issue 9, Page(s) 2496–2507

    Abstract: There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some ... ...

    Abstract There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more potent CD33-directed therapeutics. As one limitation, CD33 antibodies typically recognize the membrane-distal V-set domain. Using various artificial CD33 proteins, in which this domain was differentially positioned within the extracellular portion of the molecule, we tested whether targeting membrane-proximal epitopes enhances the effector functions of CD33 antibody-based therapeutics. Consistent with this idea, a CD33
    MeSH term(s) Antibodies, Monoclonal, Humanized/biosynthesis ; Antibodies, Monoclonal, Humanized/chemistry ; Antineoplastic Agents, Immunological/chemistry ; Gemtuzumab/chemistry ; Humans ; Immunoconjugates/chemistry ; Immunoconjugates/pharmacology ; Immunotherapy/methods ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Sialic Acid Binding Ig-like Lectin 3/antagonists & inhibitors ; Sialic Acid Binding Ig-like Lectin 3/immunology ; Tumor Cells, Cultured
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; CD33 protein, human ; Immunoconjugates ; Sialic Acid Binding Ig-like Lectin 3 ; Gemtuzumab (93NS566KF7)
    Language English
    Publishing date 2021-02-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-021-01160-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Development of [

    Laszlo, George S / Orozco, Johnnie J / Kehret, Allie R / Lunn, Margaret C / Huo, Jenny / Hamlin, Donald K / Scott Wilbur, D / Dexter, Shannon L / Comstock, Melissa L / O'Steen, Shyril / Sandmaier, Brenda M / Green, Damian J / Walter, Roland B

    Leukemia

    2022  Volume 36, Issue 6, Page(s) 1485–1491

    Abstract: Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 ( ...

    Abstract Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 (
    MeSH term(s) Acute Disease ; Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Astatine/therapeutic use ; Humans ; Interleukin-3 Receptor alpha Subunit ; Leukemia, Myeloid, Acute/drug therapy ; Mice ; Radioimmunotherapy
    Chemical Substances Antibodies, Monoclonal ; Interleukin-3 Receptor alpha Subunit ; Astatine (XI595HAL7H)
    Language English
    Publishing date 2022-04-26
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-022-01580-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Restriction of Src activity by Cullin-5.

    Laszlo, George S / Cooper, Jonathan A

    Current biology : CB

    2009  Volume 19, Issue 2, Page(s) 157–162

    Abstract: Src is a nonreceptor tyrosine kinase that coordinates responses to diverse soluble and adhesive signaling molecules and regulates cell proliferation, survival, differentiation and migration. Normally, Src activity is tightly regulated, and Src-catalyzed ... ...

    Abstract Src is a nonreceptor tyrosine kinase that coordinates responses to diverse soluble and adhesive signaling molecules and regulates cell proliferation, survival, differentiation and migration. Normally, Src activity is tightly regulated, and Src-catalyzed phosphorylation is counterbalanced by phosphotyrosine phosphatases. However, deregulated mutant Src causes malignant transformation when highly expressed. Src transformation is dose dependent, but it has been unclear how much mutant Src, compared with endogenous Src, is required for transformation. Here, we show that transformation requires high-level overexpression of mutant src mRNA, in part because active Src protein is degraded by ubiquitin-mediated proteolysis. We show that active but not inactive Src protein is downregulated depending on the putative tumor suppressor and E3 ubiquitin ligase component, Cullin-5 (Cul5). Cul5 removal synergizes with physiological levels of mutant src mRNA to increase protein tyrosine phosphorylation, induce morphological transformation, and deregulate growth. Cul5 also represses Src-induced tumorigenesis and regulates Src signaling in normal cells. These results suggest that, when Src is activated by mutation or physiological mechanisms, its effects are limited by Cul5, which downregulates active Src and its phosphorylated substrates. These findings demonstrate the importance of a new mechanism that downregulates Src signaling in cells.
    MeSH term(s) Animals ; Cell Line ; Cell Transformation, Neoplastic ; Cullin Proteins/genetics ; Cullin Proteins/metabolism ; Enzyme Activation ; Fibroblasts/cytology ; Fibroblasts/physiology ; Mice ; Mice, Knockout ; Mice, Nude ; Neoplasm Transplantation ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Signal Transduction/physiology ; Survival Rate ; Transplantation, Heterologous ; src-Family Kinases/genetics ; src-Family Kinases/metabolism
    Chemical Substances Cullin Proteins ; Protein Isoforms ; src-Family Kinases (EC 2.7.10.2)
    Language English
    Publishing date 2009-01-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1071731-6
    ISSN 1879-0445 ; 0960-9822
    ISSN (online) 1879-0445
    ISSN 0960-9822
    DOI 10.1016/j.cub.2008.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top